Pharmaceutical Executive
How do you generate excitement for 5,000 sales reps who promote a product in a changing marketplace? You give them VIP tickets to the Plavix Plan of Action Premiere and reenact a blockbuster Hollywood movie debut! Of course it helps to build anticipation, which is exactly what Torre Lazur McCann did with its six-week direct mail campaign to get Bristol-Myers Squibb and Sanofi-Aventis' sales reps ready for the big event.
LIVING PROOF
Torre Lazur McCann
BRAND Plavix CLIENT Bristol-Myers Squibb/Sanofi-Aventis FROM LEFT: Jennifer Mulvaney, senior vice president, creative director, art; Marcia Goddard, senior vice president, creative director, copy; David Trent, vice president, associate creative director, copy; Nancy Schroeter, vice president, associate creative director, art; Mary White, vice president, management supervisor
How do you generate excitement for 5,000 sales reps who promote a product in a changing marketplace? You give them VIP tickets to the Plavix Plan of Action Premiere and reenact a blockbuster Hollywood movie debut! Of course it helps to build anticipation, which is exactly what Torre Lazur McCann did with its six-week direct mail campaign to get Bristol-Myers Squibb and Sanofi-Aventis' sales reps ready for the big event.
"The tendency is to communicate everything electronically," says Nancy Schroeter, vice president, associate creative director, art. "We proposed the idea to the client that if you get something in the mail that's dimensional, you'll open it."
The agency mailed six pieces for the campaign (right, below) which included a kit that rolled out a red carpet and another that included real microwave popcorn with a specialized printed message. The final mailer sent VIP tickets to enter the Plavix Premiere. Box-office soared: "We created anticipation and were able to reinforce the brand message and tease the new campaign," says Mary White, vice president, management supervisor. "Once the sales force arrived at the meeting, we had other things to help bring the campaign to life."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.